Lisinopril vs Losartan in Special Populations: A Head-to-Head Comparison

How Lisinopril and Losartan Differ Mechanistically

Lisinopril blocks angiotensin-converting enzyme, preventing the conversion of angiotensin I to angiotensin II. Losartan competitively blocks the AT1 receptor, the receptor that angiotensin II binds to produce vasoconstriction and aldosterone release. Both drugs reduce blood pressure by roughly 10-15 mmHg systolic at standard doses, yet their downstream effects diverge in ways that matter clinically.

The Bradykinin Difference

When ACE is blocked by lisinopril, bradykinin accumulates. Bradykinin causes vasodilation, which may add to blood pressure lowering, but it also irritates airway afferent nerves. That irritation produces the dry, nonproductive cough reported by 10-15% of patients on ACE inhibitors, and more frequently in women and patients of East Asian ancestry. [1] Losartan does not inhibit ACE, so bradykinin does not accumulate and cough rates stay below 3%.

Uric Acid: A Losartan-Specific Benefit

Losartan blocks the URAT1 uric acid transporter in the proximal tubule, producing a modest uricosuric effect. In patients with gout or hyperuricemia alongside hypertension, this property may be clinically useful. Lisinopril has no uricosuric activity. A 2010 analysis in the Journal of Hypertension found losartan reduced serum uric acid by approximately 0.8 mg/dL compared with other antihypertensives. [2]

Tissue ACE Inhibition vs. Receptor Blockade

Lisinopril inhibits both circulating and tissue-bound ACE. Some researchers hypothesize that tissue ACE inhibition contributes to cardioprotection beyond blood pressure reduction alone, particularly in the myocardium and kidney. Whether this translates to a clinically meaningful difference in hard endpoints over losartan remains debated and has not been definitively resolved in a single head-to-head outcomes trial powered for mortality.

Head-to-Head Trial Evidence: What the Data Actually Show

Two large randomized controlled trials form the backbone of the comparison, and their populations were deliberately different.

ALLHAT (2002): Lisinopril vs. Chlorthalidone in a Diverse Cohort

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT, N=33,357) randomized high-risk hypertensive adults to chlorthalidone, amlodipine, or lisinopril. The lisinopril arm was not compared against losartan, but ALLHAT remains central because it enrolled 35% Black patients, a group in whom ACE inhibitor monotherapy consistently showed inferior blood pressure control compared with chlorthalidone. [3] Combined cardiovascular disease events were higher with lisinopril than chlorthalidone in Black participants (RR 1.19, 95% CI 1.09-1.30, P<0.001). This finding shaped current JNC and AHA/ACC guideline language recommending thiazide diuretics or calcium channel blockers as preferred first-line therapy in non-diabetic Black patients with hypertension.

LIFE (2002): Losartan vs. Atenolol in LVH Patients

The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial (N=9,193) compared losartan-based therapy against atenolol-based therapy in hypertensive patients with electrocardiographic left ventricular hypertrophy (LVH). [4] Losartan reduced the composite of cardiovascular death, stroke, and MI by 13% relative to atenolol (RR 0.87, 95% CI 0.77-0.98). The stroke reduction was the dominant driver: losartan cut stroke risk by 25% (RR 0.75, P=0.001) despite similar blood pressure lowering between arms. A pre-specified subgroup of 1,195 patients with diabetes showed a 37% relative reduction in the composite endpoint with losartan versus atenolol. [4]

The LIFE trial did not compare losartan against lisinopril directly. However, because no equivalent trial has shown the same magnitude of stroke reduction with an ACE inhibitor in LVH patients, most guidelines designate losartan as the preferred agent when LVH regression and stroke prevention are primary treatment goals.

Interpreting the Gap in Head-to-Head Data

No single randomized trial has compared lisinopril versus losartan as the primary intervention on mortality endpoints in an adequately powered general hypertension cohort. A 2015 network meta-analysis of 147 trials in the BMJ (N=464,000 participants) found ACE inhibitors and ARBs produced nearly identical reductions in major cardiovascular events when blood pressure lowering was equivalent. [5] The practical implication: for most patients without a population-specific indication, the choice between lisinopril and losartan rests on tolerability, comorbidities, and patient preference rather than a clear mortality advantage for either drug.

Special Population Guidance

Chronic Kidney Disease and Diabetic Nephropathy

Both drugs reduce intraglomerular pressure by dilating the efferent arteriole and slow the progression of proteinuric CKD. The RENAAL trial (N=1,513) demonstrated that losartan 100 mg reduced the risk of doubling serum creatinine, ESRD, or death by 16% versus placebo in patients with type 2 diabetes and nephropathy (P=0.02). [6] Comparable evidence for lisinopril in diabetic nephropathy comes from the EUCLID trial and earlier small studies showing albuminuria reduction.

The 2024 KDIGO guidelines state that an ACE inhibitor or ARB is recommended for adults with diabetes, hypertension, and urine albumin-to-creatinine ratio (uACR) above 30 mg/g. [7] Neither agent is designated as superior to the other for this indication in the current guideline text. Combining lisinopril with losartan is explicitly contraindicated. The ONTARGET trial (N=25,620) showed dual blockade with ramipril plus telmisartan doubled renal adverse events (hypotension, hyperkalemia, dialysis) without reducing cardiovascular mortality. [8]

Heart Failure with Reduced Ejection Fraction (HFrEF)

Lisinopril's Role Post-MI

The GISSI-3 trial (N=18,895) assigned patients with acute MI to lisinopril, transdermal nitroglycerin, both, or neither. Lisinopril reduced 6-week mortality by 11% (OR 0.88, P=0.03). [9] The 2022 AHA/ACC Heart Failure Guideline gives ACE inhibitors a Class I recommendation for HFrEF as mortality-reducing therapy. [10]

Where ARBs Fit

Losartan and valsartan are recommended as substitutes when ACE inhibitor cough is intolerable. The Val-HeFT trial showed valsartan reduced heart failure hospitalizations in patients already on ACE inhibitors. The HEAAL trial compared losartan 150 mg versus 50 mg and found the higher dose reduced death or hospitalization for heart failure by 10% (HR 0.90, P=0.025). [11] For patients intolerant of ACE inhibitors, losartan at 50-150 mg is a guideline-supported alternative. Sacubitril/valsartan has largely supplanted both in patients who can tolerate an ARNI, but cost and access remain barriers for many.

Hypertension in Black Patients

Blood pressure response to monotherapy with ACE inhibitors or ARBs is blunted in Black patients compared with white patients because of the lower-renin phenotype more prevalent in this population. ALLHAT documented a 4 mmHg greater systolic reduction with chlorthalidone versus lisinopril in Black participants. [3] The 2021 AHA/ACC Hypertension Guideline recommends a thiazide-type diuretic or calcium channel blocker as preferred initial therapy in Black adults without heart failure or CKD. [12] When proteinuria or CKD is present, an ACE inhibitor or ARB is added regardless of race, and both are acceptable. Combining a dihydropyridine CCB with an ACE inhibitor or ARB addresses the lower-renin physiology more effectively than either renin-angiotensin blocking drug alone.

Left Ventricular Hypertrophy

Losartan is the only antihypertensive with a dedicated large-scale RCT (LIFE) showing superior stroke reduction in this specific phenotype. The 2021 AHA/ACC guideline notes that losartan may be preferred in hypertensive patients with LVH to reduce stroke risk. [12] The LIFE investigators wrote: "Losartan seems to have benefits beyond blood pressure reduction for prevention of cardiovascular morbidity and mortality." [4] Lisinopril lacks comparable LVH-specific outcomes data; choosing between them when LVH is present on ECG or echo generally favors losartan.

Diabetic Patients Without CKD

Both drugs reduce microalbuminuria progression. The main differentiating factor in this group is tolerability. Cough affects up to 15% of ACE inhibitor users and is disproportionately common in patients of South Asian, East Asian, or African descent, populations that overlap heavily with type 2 diabetes prevalence. Losartan avoids this side effect without sacrificing renal protection. The 2024 ADA Standards of Care state an ACE inhibitor or ARB is indicated in patients with diabetes and uACR above 30 mg/g or hypertension and CKD, and the choice between them may be guided by tolerability and patient preference. [13]

Gout and Hyperuricemia

Thiazide diuretics raise uric acid. When a hypertensive patient with gout requires a second antihypertensive, losartan's mild uricosuric effect makes it a logical choice over lisinopril. No head-to-head RCT has compared the two specifically for gout outcomes, but observational data from a 2012 analysis in Arthritis and Rheumatism (N=5,789) found losartan use was associated with a 19% lower risk of incident gout compared with other antihypertensives after adjustment. [14]

Pregnancy and Women of Childbearing Age

Both lisinopril and losartan are teratogenic. Both are classified as contraindicated from the second trimester onward due to fetal renal dysgenesis, oligohydramnios, skull hypoplasia, and neonatal renal failure. First-trimester exposure carries a lower but still elevated risk. The FDA labeling for both drugs states: "When pregnancy is detected, discontinue [drug] as soon as possible." [15] Women of reproductive potential should use effective contraception and be counseled to notify their prescriber immediately upon discovering pregnancy. Methyldopa, labetalol, and nifedipine are the preferred antihypertensives during pregnancy.

Elderly Patients and Orthostatic Hypotension

Both drugs carry an orthostatic hypotension risk in older adults, particularly when combined with diuretics. Losartan's peak antihypertensive effect occurs roughly 6 hours after dosing; lisinopril peaks at 6-8 hours. Neither agent is clearly superior for avoiding first-dose hypotension in the elderly. Starting doses should be low: lisinopril 2.5-5 mg daily, losartan 25 mg daily. The 2023 American Geriatrics Society Beers Criteria does not list either drug as potentially inappropriate in older adults when used for a standard indication with appropriate monitoring. [16]

Side Effect Profile Compared

Cough

ACE inhibitor cough develops in 10-15% of users on lisinopril. [1] It is typically dry, ticklish, and nocturnal. It resolves within 1-4 weeks of stopping the drug. Switching to losartan eliminates this adverse effect in the vast majority of patients. This is the most common clinically actionable difference between the two drugs.

Angioedema

Lisinopril-associated angioedema occurs in approximately 0.3-0.7% of patients overall, with a 3-5 times higher incidence in Black patients. [17] It can be life-threatening when it involves the larynx. Losartan carries a much lower angioedema risk (approximately 0.1%), but patients who develop ACE inhibitor angioedema should not be switched to an ARB without careful consideration. The shared mechanism of potentiating bradykinin to a lesser degree, combined with cross-reactivity reports, means that some authors recommend a 4-6 week washout and close monitoring if an ARB is selected after ACE inhibitor angioedema.

Hyperkalemia

Both drugs reduce aldosterone-driven potassium excretion and can cause hyperkalemia. Risk rises sharply with eGFR below 45 mL/min/1.73m², concurrent potassium-sparing diuretics, NSAIDs, or potassium supplementation. A 2023 Cochrane review of renin-angiotensin system inhibitors in CKD found hyperkalemia-related discontinuation rates of approximately 5-8% in patients with eGFR below 30 mL/min/1.73m². [18] Baseline and 1-4 week follow-up potassium and creatinine checks are standard when initiating either drug.

Renal Function Changes

A rise in serum creatinine of up to 30% above baseline within the first 2-4 weeks of starting either drug is expected and generally acceptable as a sign that efferent arteriolar dilation is occurring. A rise greater than 30% should prompt evaluation for bilateral renal artery stenosis or volume depletion before continuing treatment.

When and How to Switch from Lisinopril to Losartan

Switching is straightforward in most cases. Persistent cough is the most common and best-supported reason. The transition does not require a washout period for cough. Angioedema requires individual risk-benefit assessment before switching, as discussed above.

Approximate Dose Equivalences

These are approximate clinical equivalences, not pharmacokinetically validated ratios:

• Lisinopril 5 mg corresponds roughly to losartan 25 mg
• Lisinopril 10 mg corresponds roughly to losartan 50 mg
• Lisinopril 20-40 mg corresponds roughly to losartan 100 mg

Monitoring After the Switch

Check blood pressure at 2-4 weeks. Recheck potassium and creatinine at 2-4 weeks, particularly if eGFR is below 60 mL/min/1.73m². Blood pressure may change modestly because the two drugs have slightly different dose-response relationships. Cough should resolve within 1-4 weeks of stopping lisinopril.

When Not to Switch

Do not substitute losartan (or any ARB) for lisinopril in a patient who experienced angioedema on lisinopril without a formal risk-benefit discussion and close follow-up monitoring in place. The FDA warns that ARBs are not automatically safe alternatives in this scenario. [15]

Practical Prescribing Summary

Choosing between lisinopril and losartan in 2025 depends less on a single head-to-head mortality trial (which does not exist) and more on the specific patient in front of you. The table below consolidates the population-level guidance.

| Clinical Scenario | Preferred Agent | Key Evidence | |---|---|---| | Hypertensive LVH | Losartan | LIFE trial [4] | | Post-MI HFrEF | Lisinopril | GISSI-3 [9], Class I AHA [10] | | ACE inhibitor cough | Switch to losartan | Mechanism; <3% cough rate | | ACE inhibitor angioedema | ARB with caution or avoid | FDA labeling [15] | | CKD with proteinuria | Either; do not combine | KDIGO 2024 [7] | | Hypertension in Black patients | Add CCB or thiazide first | ALLHAT [3], AHA/ACC [12] | | Gout/hyperuricemia | Losartan preferred | Uricosuric effect [2] | | Diabetes with uACR >30 | Either | ADA 2024 [13] | | Pregnancy | Neither; stop immediately | FDA [15] |

For a patient with uncomplicated hypertension, no LVH, and no cough, either drug is acceptable. Lisinopril 10 mg once daily and losartan 50 mg once daily are reasonable starting points that can be titrated up over 4 weeks based on blood pressure response.